Investment

Illumina Gets European Commission Order to Divest Grail

1 Mins read

By Ben Glickman


Illumina is evaluating divestiture options for Grail after the European Commission ruled the gene-sequencing company had 12 months to sell the recently acquired business.

The San Diego-based company said Friday that it could explore a third-party sale or a capital markets transaction under the EC’s order, which allows for flexibility in the structure of the divestiture. The company also may be able to extend the deadline to complete the divestiture by three additional months.

Illumina acquired the cancer-test developer Grail for $7.1 billion in 2021, but the deal was blocked last year by regulators over antitrust concerns.

Illumina said Friday that it still believed the EC did not have jurisdiction over its acquisition. The company has challenged the EC’s jurisdiction in the European Court of Justice, and a decision in the case is pending.


Write to Ben Glickman at [email protected]


Read the full article here

Related posts
Investment

Opinion: The top 10% of Americans are propping up the economy. Here’s what will happen if they stop spending. 

1 Mins read
Outside the Box The wealthy are spending, but many consumers are pulling back — and the stock market is fragile Last Updated:…
Investment

AMC’s most liquid bond is rallying following the movie-theater chain’s fourth-quarter results

1 Mins read
Published: Feb. 27, 2025 at 1:23 p.m. ET AMC Entertainment Holdings Inc.’s most liquid bond rallied this week, lifted by better-than-expected fourth-quarter revenue…
Investment

Okta delivers what some of its bigger peers couldn’t: a rosy outlook

1 Mins read
Last Updated: March 3, 2025 at 8:14 p.m. ETFirst Published: March 3, 2025 at 4:38 p.m. ET Not all software companies are giving upbeat…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *